 |
5 Diseases |  |
0 Trials |
|
0 Trials |  |
14 News |  |
- ||| Vantas (histrelin acetate) / Orion Corp, Endo
Strong work by Dr. Roshanak Markley, @CoryRTrankle @JenJordanPhD @GregHundleyMD @bvantassell and rest of the team @VCUHealthHeart Abnormal left ventricular subendocardial perfusion and diastolic function in women with obesity and heart failure a… https://t.co/7qaSE8IUM0 (Twitter) - Jan 8, 2023
- || Vantas (histrelin acetate) / Orion Corp, Endo
Congratulations @bvantassell on a tremendous (and deserved) honor. Cheers! (Twitter) - Jul 27, 2022
- || Vantas (histrelin acetate) / Orion, Endo
Clinical, Journal: Comparative Efficacy of Histrelin Acetate and hCG for Inducing Ovulation in Brazilian Northeastern Jennies (Equus africanus asinus). (Pubmed Central) - Mar 16, 2021
All jennies from G1 and G2 ovulated up to 48 hours after ovulation induction, whereas 100% of jennies in the control cycle ovulated later (>48 hours from the administration of saline). In conclusion, both histrelin acetate and hCG at the used dose are efficient ovulation-inducing agents in jennies promoting ovulation up to 48 hours after administration.
- | Vantas (histrelin acetate) / Orion, Endo
Journal: Histrelin Implants for Suppression of Puberty in Youth with Gender Dysphoria: A Comparison of 50 mcg/Day (Vantas) and 65 mcg/Day (SupprelinLA). (Pubmed Central) - Mar 2, 2021
These results indicate that both implants are effective in suppressing puberty in early-to-mid pubertal youth with gender dysphoria. These data may inform decisions about insurance coverage of Supprelin and/or Vantas for youth with gender dysphoria.
- |||| Clinical: The Pediatric Endocrine Society lists these medications for puberty suppression.... Leuprolide acetate depot/Lupron Depot Triptorelin/Triptodur Histrelin acetate/Supprelin LA and Vantas https://t.co/AMkOO1M63D (Twitter) - Sep 21, 2019
- ||| Vantas (histrelin acetate) / Orion Corp, Endo
Trial completion, Enrollment change, Metastases: THE VANTAS STUDY: Prospective Multicentre Non-interventional Study of VANTAS (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=142, Completed, Sponsor: Orion Corporation, Orion Pharma
These data may inform decisions about insurance coverage of Supprelin and/or Vantas for youth with gender dysphoria. Recruiting --> Completed | N=300 --> 142
- |||||||||| Vantas (histrelin acetate) / Orion Corp, Endo
New P3 trial, Metastases: Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer (clinicaltrials.gov) - Sep 30, 2012
P3, N=138, Completed, Sponsor: Endo Pharmaceuticals
- ||| Vantas (histrelin acetate) / Orion Corp, Endo
Metastases: THE VANTAS STUDY: Prospective Multicentre Non-interventional Study of VANTAS (clinicaltrials.gov) - Apr 8, 2012
P=N/A, N=300, Recruiting, Sponsor: Orion Corporation, Orion Pharma